Cohort | Subtypes | Treatment response | All patients | cN2–3 | cN1 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSH-YCC | HR+ HER2− | ALN+ | ALN− | FNRa | ALN+ | ALN− | FNRa | ALN+ | ALN− | FNRa | ||||
Complete MRI response | SLN+ | 11 | 0 | 31.3% (8.6–54.0) | SLN+ | 2 | 0 | 50.0% (1.0–99.0) | SLN+ | 9 | 0 | 25.0% (0.5–49.5) | ||
SLN− | 5 | 9 | SLN− | 2 | 4 | SLN− | 3 | 5 | ||||||
Non-complete MRI response | SLN+ | 110 | 0 | 20.9% (14.1–27.6) | SLN+ | 44 | 0 | 17.0% (6.9–27.1) | SLN+ | 66 | 0 | 23.3% (14.3–32.2) | ||
SLN− | 29 | 43 | SLN− | 9 | 7 | SLN− | 20 | 36 |
HER2+ or TNBC | ALN+ | ALN− | FNRa | ALN+ | ALN− | FNRa | ALN+ | ALN− | FNRa | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Complete MRI response | SLN+ | 6 | 0 | 0.0% | SLN+ | 0 | 0 | 0.0% | SLN+ | 6 | 0 | 0.0% | ||
SLN− | 0 | 24 | SLN− | 0 | 11 | SLN− | 0 | 13 | ||||||
Non-complete MRI response | SLN+ | 36 | 0 | 33.3% (20.8–45.9) | SLN+ | 16 | 0 | 23.8% (6.0–42.0) | SLN+ | 20 | 0 | 39.4% (22.7–56.1) | ||
SLN− | 18 | 97 | SLN− | 5 | 30 | SLN− | 13 | 67 |
AMC-SMC | HER2+ or TNBC | ALN+ | ALN− | FNRa | ALN+ | ALN− | FNRa | ALN+ | ALN− | FNRa | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Complete MRI response | SLN+ | 26 | 0 | 7.1% (0–16.7) | SLN+ | 14 | 0 | 6.7% (0–19.3) | SLN+ | 12 | 0 | 7.7% (0–22.2) | ||
SLN− | 2 | 19 | SLN− | 1 | 4 | SLN− | 1 | 15 | ||||||
Non-complete MRI response | SLN+ | 105 | 0 | 11.8% (6.0–17.6) | SLN+ | 47 | 0 | 9.6% (1.6–17.6) | SLN+ | 58 | 0 | 13.4% (5.3–21.6) | ||
SLN− | 14 | 100 | SLN− | 5 | 20 | SLN− | 9 | 80 |